Subscribe to RSS
DOI: 10.5999/aps.2016.43.6.491
Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model
Background Hypertrophic scarring is a pathological condition that occurs after trauma or surgery. Angiogenesis occurs more often with hypertrophic scarring than with normotrophic scarring. The regulation of angiogenesis is one of the key factors in hypertrophic scar management. Vascular endothelial growth factor (VEGF) is an essential factor in the angiogenetic response. This study investigated whether decreasing the level of VEGF is effective for treating hypertrophic scarring.
Methods Ten 8-week-old female New Zealand white rabbits were included. Four defects were created on each ear by using a 6-mm punch. Bevacizumab (Avastin, Roche Pharma, Basel, Switzerland) was administered in one ear and normal saline was administered in the other ear. Treatment was administered starting on day 2, every 2 days, until day 14. The levels of VEGF were measured using enzyme-linked immunosorbent assay on day 10 and histologic results were analyzed on day 40.
Results Bevacizumab induced-defects showed less hypertrophic scarring when compared with the control group as measured by the scar elevation index (SEI) and loose collagen arrangement. The SEI in the experimental group was 1.89±0.13, compared to 1.99±0.13 in the control group (n=30, P=0.005). Additionally, the VEGF level was lower (38.72±11.03 pg vs. 82.50±21.64 pg, n=10, P=0.001) and fewer vessels existed (8.58±0.76 vs. 7.2±1.20, n=10, P=0.007).
Conclusions Preventing excessive angiogenesis is effective for preventing scar formation, especially with hypertrophic scarring. Although it is not an approach that is sufficient alone for the management of scarring, it may be one of several important strategies for scar treatment.
Keywords
Cicatrix, hypertrophic - Neovascularization, pathologic - Bevacizumab - Angiogenesis inhibitorsPublication History
Received: 24 March 2016
Accepted: 31 August 2016
Article published online:
20 April 2022
© 2016. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 2010; 125: 557-568
- 2 DiPietro LA. Angiogenesis and scar formation in healing wounds. Curr Opin Rheumatol 2013; 25: 87-91
- 3 van der Veer WM, Niessen FB, Ferreira JA. et al. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen 2011; 19: 292-301
- 4 Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000; 9: 413-418
- 5 Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529
- 6 Bock O, Schmid-Ott G, Malewski P. et al. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433-438
- 7 Ong CT, Khoo YT, Tan EK. et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007; 211: 95-108
- 8 Danese S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007; 23: 384-389
- 9 Maruotti N, Cantatore FP, Crivellato E. et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21: 557-566
- 10 Nomoto H, Shiraga F, Kuno N. et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-4813
- 11 Sinapis C, Routsias J, Sinapis D. et al. Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits. Invest Ophthalmol Vis Sci 2010; 51: 2440
- 12 Wang J, Chen H, Shankowsky HA. et al. Improved scar in postburn patients following interferon-alpha2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor. J Interferon Cytokine Res 2008; 28: 423-434
- 13 Wilgus TA, Ferreira AM, Oberyszyn TM. et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008; 88: 579-590
- 14 Morris DE, Wu L, Zhao LL. et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg 1997; 100: 674-681
- 15 Ko JH, Kim PS, Zhao Y. et al. HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model. Plast Reconstr Surg 2012; 129: 252e-262e
- 16 Weidner N. Chapter 14. Measuring intratumoral microvessel density. Methods Enzymol 2008; 444: 305-323
- 17 Ren HT, Hu H, Li Y. et al. Endostatin inhibits hypertrophic scarring in a rabbit ear model. J Zhejiang Univ Sci B 2013; 14: 224-230
- 18 Mello GR, Pizzolatti ML, Wasilewski D. et al. The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model. Clinics (Sao Paulo) 2011; 66: 1443-1450